A Study to Access Intravenous (IV) Telisotuzumab Adizutecan in Combination With IV Bevacizumab Compared to Standard of Care IV Bevacizumabin Combination With Oral Trifluridine and Tipiracil in Adult Participants With Refractory Metastatic Colorectal Cancer
Condition(s) studied
Investigational drug(s) / intervention(s)
Telisotuzumab adizutecan: Intravenous (IV)
Bevacizumab: Intravenous (IV)
Trifluridine/Tipiracil: Oral
Study summary
Colorectal cancer (CRC) is the third most common type of cancer diagnosed worldwide. The purpose of this study is to assess the adverse events and change in disease activity of telisotuzumab adizutecan plus bevacizumab compared to standard of care (SOC) of LONSURF (trifluridine and tipiracil) plus bevacizumab in adult participants with refractory metastatic colorectal cancer (mCRC).
Telisotuzumab adizutecan is an investigational drug being developed for the treatment of CRC. Participants will then be randomized into 2 groups called treatment arms. One group will receive telisotuzumab adizutecan with bevacizumab in different doses. Another group will receive standard of care (SOC), trifluridine and tipiracil (LONSURF), with Bevacizumab. Up to approximately 990 adult participants with refractory mCRC, will be enrolled in the study in approximately 125 sites globally.
In this Phase 3, one of two groups will receive doses of Intravenous (IV) telisotuzumab adizutecan + bevacizumab and other group will receive oral SOC of trifluridine/tipiracil (LONSURF)+ Intravenous (IV) bevacizumab. The study will run for a duration of approximately of 36 months.
There may be higher treatment burden for participants in this trial compared to their standard of care. Participants will attend regular visits during the study at an approved institution (hospital or clinic). The effect of the treatment will be frequently checked by medical assessments, blood tests, questionnaires and side effects.
Eligibility
Primary outcome measure(s)
- Phase 3: Objective Response (OR) as assessed by Blinded Independent Central Review (BICR) — Up to Approximately 15 Months
Best overall response of confirmed complete response (CR) or confirmed partial response (PR) per Response Evaluation Criteria in Solid Tumors (RECIST) v1.1. - Phase 3: Overall Survival (OS) — Up to Approximately 36 Months
OS is defined as the time from date of randomization to the event of death from any cause.
Trial sites (88)
| Facility | City | Region | Status |
|---|---|---|---|
| City Of Hope - Phoenix /ID# 279450 | Goodyear | Arizona | Recruiting |
| Highlands Oncology Group - Springdale /ID# 279444 | Springdale | Arkansas | Recruiting |
| City of Hope National Medical Center /ID# 279449 | Duarte | California | Recruiting |
| Rocky Mountain Cancer Centers - Aurora /ID# 280112 | Aurora | Colorado | Recruiting |
| Yale University School of Medicine /ID# 279373 | New Haven | Connecticut | Recruiting |
| Moffitt Cancer Center /ID# 279325 | Tampa | Florida | Recruiting |
| City Of Hope - Atlanta /ID# 280017 | Newnan | Georgia | Recruiting |
| University of Chicago Medical Center /ID# 279365 | Chicago | Illinois | Recruiting |
| Saint Lukes Hospital of Kansas City /ID# 279513 | Kansas City | Missouri | Recruiting |
| Astera Cancer Care /ID# 279532 | East Brunswick | New Jersey | Recruiting |
| Northwell Health Center for Advanced Medicine. /ID# 279590 | Lake Success | New York | Recruiting |
| Duke University Medical Center /ID# 279322 | Durham | North Carolina | Recruiting |
| Oncology Hematology Care - Blue Ash /ID# 280143 | Cincinnati | Ohio | Recruiting |
| Compass Oncology - Rose Quarter /ID# 280127 | Portland | Oregon | Recruiting |
| Texas Oncology - Abilene - Antilley Road /ID# 280120 | Abilene | Texas | Recruiting |
| The University of Texas MD Anderson Cancer Center /ID# 279865 | Houston | Texas | Recruiting |
| Blue Ridge Cancer Care - Blacksburg /ID# 280115 | Blacksburg | Virginia | Recruiting |
| University Of Washington /ID# 281451 | Seattle | Washington | Recruiting |
| Imelda Ziekenhuis /ID# 279333 | Bonheiden | Antwerpen | Recruiting |
| Universitair Ziekenhuis Antwerpen /ID# 279334 | Edegem | Antwerpen | Recruiting |
| Institut Jules Bordet /ID# 279406 | Anderlecht | Brussels Capital | Recruiting |
| Cliniques Universitaires UCL Saint-Luc /ID# 279335 | Brussels | Brussels Capital | Recruiting |
| Universitair Ziekenhuis Brussel /ID# 279535 | Jette | Brussels Capital | Recruiting |
| Grand Hopital de Charleroi - Les Viviers /ID# 279336 | Charleroi | Hainaut | Recruiting |
| Universite Catholique de Louvain-Namur - Centre Hospitalier Universitaire Dinant /ID# 280014 | Yvoir | Namur | Recruiting |
| AZ Maria Middelares /ID# 280141 | Ghent | Oost-Vlaanderen | Recruiting |
| Universitair Ziekenhuis Leuven /ID# 279330 | Leuven | Vlaams-Brabant | Recruiting |
| AZ-Delta. /ID# 279329 | Roeselare | West-Vlaanderen | Recruiting |
| Beijing Hospital No. 2 /ID# 279666 | Beijing | Beijing Municipality | Recruiting |
| Beijing Friendship Hospital /ID# 279766 | Beijing | Beijing Municipality | Recruiting |
| Sun Yat-Sen University Cancer Center /ID# 279670 | Guangzhou | Guangdong | Recruiting |
| Zhujiang Hospital /ID# 279667 | Guangzhou | Guangdong | Recruiting |
| Guangxi Medical University Cancer Hospital /ID# 279707 | Nanning | Guangxi | Recruiting |
| Harbin Medical University Cancer Hospital /ID# 279961 | Harbin | Heilongjiang | Recruiting |
| Henan Cancer Hospital /ID# 279678 | Zhengzhou | Henan | Recruiting |
| Union Hospital - Tongji Medical College /ID# 283649 | Wuhan | Hubei | Recruiting |
| Hubei Cancer Hospital /ID# 279687 | Wuhan | Hubei | Recruiting |
| Affiliated Hospital Of Jiangnan University(Wuxi Fourth People'S Hospital ) /ID# 280200 | Wuxi | Jiangsu | Recruiting |
| China-Japan Union Hospital /ID# 279801 | Changchun | Jilin | Recruiting |
| The Fourth Affiliated Hospital of China Medical University /ID# 279799 | Shenyang | Liaoning | Recruiting |
+ 48 more sites — see the full list on the official registry below.
On this site
📄 Avastin (bevacizumab) drug profile →More AbbVie trials in Portugal
Other trials for the same condition
This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.
View NCT07525206 on ClinicalTrials.gov ↗ ← All trials in Portugal